EUVIMEDEUVIMED entdecken
Crossref

Improved Oral Health in Adults With X-Linked Hypophosphatemia Treated With Burosumab

Agathe Hervé, Margaux Gadion, Julia Herrou iD, Mathieu Izart, Agnès Linglart iD, Martine Cohen-Solal, Anne-Lise Lecoq iD, Peter Kamenicky iD, Karine Briot iD, Catherine Chaussain iD, Martin Biosse Duplan iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Agathe Hervé und 10 weiteren Autor:innen. Beteiligte Einrichtung: UFR Odontologie, Université Paris Cité and AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, FHU DDS-…. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets, Antibodies, Monoclonal, Humanized, Oral Health. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

X-linked hypophosphatemia (XLH) is a rare genetic bone disease affecting both children and adults, with oral manifestations such as spontaneous dental infections. The main treatments for XLH are conventional treatment (CT) with oral phosphate salts and active vitamin D supplementation and burosumab, an antibody targeting fibroblast growth factor 23. While the beneficial effect of CT on oral manifestations is established, the effect of burosumab on oral health is unknown, especially in adults.

Objective

We aimed to compare the oral health (number of missing or endodontically treated teeth and presence of periodontal disease) and incidence of endodontic infections of adult patients with XLH according to their treatment's modalities (no treatment, CT, or burosumab).

Methods

This was achieved through a single-center, retrospective analysis of oral health data from 44 patients who had undergone dental monitoring for at least 6 months.

Results

Oral health varied according to the proportion of their adult life spent under treatment for XLH, and the incidence of dental infections during follow-up was influenced by the type of treatment received. There was a 55.9% reduction of infections during CT and an 86.4% reduction during burosumab treatment compared to periods with no treatment (P < .0001). Comparing treatment and nontreatment periods within the same patient showed a strong association between burosumab treatment and decreased infection incidence (.006 vs .09 infection per month, P < .01).

Conclusion

We observed that adults with XLH treated with burosumab developed fewer endodontic infections during dental follow-up than patients who were untreated or received CT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Familial Hypophosphatemic RicketsAntibodies, Monoclonal, HumanizedOral HealthHumansMaleFemaleAdultRetrospective StudiesMiddle AgedYoung AdultFibroblast Growth Factor-23AgedPeriodontal DiseasesAdolescentTreatment Outcome

Stichwörter der Autor:innen

FGF23X-linked hypophosphatemiaburosumabdental abscessperiodontitis

Substanzen

burosumabAntibodies, Monoclonal, HumanizedFibroblast Growth Factor-23

Autor:innen und Institutionen

  • UFR Odontologie, Université Paris Cité and AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, FHU DDS-net, ERN BOND, Department of Dental Medicine, Bretonneau Hospital, 750…
  • UFR de médecine, Université Paris Cité and AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, ERN BOND, Department of Rheumatology, Cochin Hospital, 75014 Paris, France.
  • AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, Endo-ERN and ERN BOND, Department of Endocrinology and Diabetology for Children, Bicêtre Paris Saclay Hospital and Univer…
  • AP-HP, Reference Center for Rare Bone Diseases, OSCAR Network, Department of Rheumatology, Lariboisiere Hospital and Université Paris Cité, INSERM 1132, 75010 Paris, France.
  • AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, Endo-ERN and ERN BOND, Department of Endocrinology, Bicêtre Paris Saclay Hospital and Université Paris Saclay, INSERM UMR…
  • Université Paris Cité, Laboratory URP2496 Orofacial Pathologies, Imaging and Biotherapies, 92120 Montrouge, France.

ORCID-Profile: Julia Herrou, Agnès Linglart, Anne-Lise Lecoq, Peter Kamenicky, Karine Briot, Catherine Chaussain, Martin Biosse Duplan

Zitieren

APA

Hervé, A., Gadion, M., Herrou, J., Izart, M., Linglart, A., Cohen-Solal, M., Lecoq, A. L., Kamenicky, P., Briot, K., Chaussain, C., & Biosse Duplan, M. (2025). Improved Oral Health in Adults With X-Linked Hypophosphatemia Treated With Burosumab. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae398

Vancouver

Hervé A, Gadion M, Herrou J, Izart M, Linglart A, Cohen-Solal M, et al. Improved Oral Health in Adults With X-Linked Hypophosphatemia Treated With Burosumab. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae398

BibTeX
@article{Herv2025,
  author = {Hervé, Agathe and Gadion, Margaux and Herrou, Julia and Izart, Mathieu and Linglart, Agnès and Cohen-Solal, Martine and Lecoq, Anne-Lise and Kamenicky, Peter and Briot, Karine and Chaussain, Catherine and Biosse Duplan, Martin},
  title = {Improved Oral Health in Adults With X-Linked Hypophosphatemia Treated With Burosumab},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae398}
}
Kostenlos starten →